Phase II Randomized, Placebo-Controlled Trial of PROSTVAC® (PSA-TRICOM) in Patients With Clinically Localized Prostate Cancer Undergoing Active Surveillance
Phase of Trial: Phase II
Latest Information Update: 21 Dec 2017
At a glance
- Drugs Rilimogene galvacirepvec (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 24 Jul 2015 According to Bavarian Nordic media release, first patient has been enrolled in this trial.
- 05 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.